Reviews - Stones and Infections Open access

Urine pH, citrate, and beyond: challenges of pharmaceutical stone management in daily urological practice

Authors

Published
23 June 2025
Section
Reviews - Stones and Infections
DOI
10.4081/aiua.2025.13798

Abstract

Kidney stone disease, or nephrolithiasis, is a prevalent urological condition with variable pathogenesis. Among various factors, urine pH is not only considered to be a more influential factor in stone formation and can aid in the early diagnosis and management of specific stone types such as uric acid, cystine, calcium phosphate and struvite stones, but the role of urine pH in calcium oxalate stones, which comprise most cases, is more complex. Hypocitraturia in routine evaluation is another recognizable factor in lithogenesis, and administration of citrate, a widely used agent in the conservative management of stones. corrects hypocitraturia. Citrate also alkalizes the urine and can therefore be used to dissolve and prevent uric acid stones. However, citrate can induce the formation of insoluble calcium phosphate salts, such as brushite and hydroxyapatite, which can lead to mixed stones and the development of nephrocalcinosis. To address this complexity, innovative treatments that focus on a broader inhibition of lithogenesis with pH-modifying strategies may allow for more comprehensive management. In addition, modern technological tools such as pH meters and pH-tracking mobile applications can offer personalized treatment plans, potentially improving patient outcomes. The current lack of consensus on the standard and optimal management of pH measurement and modification underscores the need for further research and greater collaboration among experts. The development of evidence-based strategies will be essential to improve prevention and nephrolithiasis.

Keywords

References

  1. Stamatelou K, Goldfarb DS. Epidemiology of kidney stones. Healthcare (Basel) 2023;11:424. DOI: https://doi.org/10.3390/healthcare11030424
  2. Ferraro PM, Taylor EN, Curhan GC. Factors associated with sex differences in the risk of kidney stones. Nephrol Dial Transplant. 2023; 38:177-183. DOI: https://doi.org/10.1093/ndt/gfac037
  3. Ziemba JB, Matlaga BR. Epidemiology and economics of nephrolithiasis. Investig Clin Urol. 2017; 58:299-306. DOI: https://doi.org/10.4111/icu.2017.58.5.299
  4. Ferraro PM, Bargagli M. Dietetic and lifestyle recommendations for stone formers. Arch Esp Urol. 2021; 74:112-22.
  5. Shekarriz B, Stoller ML. Uric acid nephrolithiasis: current concepts and controversies. J Urol. 2002; 168:1307-14. DOI: https://doi.org/10.1097/00005392-200210010-00003
  6. Carvalho M. Urinary pH in calcium oxalate stone formers: does it matter? J Bras Nefrol. 2018; 40:6-7. DOI: https://doi.org/10.1590/1678-4685-jbn-2018-00010002
  7. Spivacow FR, del Valle EE, Negri AL, et al. Biochemical diagnosis in 3040 kidney stone formers in Argentina. Urolithiasis. 2015;43:323-30. DOI: https://doi.org/10.1007/s00240-015-0778-0
  8. Souto G, Donapetry C, Calviño J, Adeva MM. Metabolic acidosis-induced insulin resistance and cardiovascular risk. Metab Syndr Relat Disord. 2011; 9:247-53. DOI: https://doi.org/10.1089/met.2010.0108
  9. Tekçe H, Aktas G, .ztürk S. A distal (type 1) renal tubular acidosis case that mimic coronary ischemia. Ren Fail. 2013; 35:1289-91. DOI: https://doi.org/10.3109/0886022X.2013.820662
  10. Hochreiter W, Knoll T, Hess B. Pathophysiology, diagnosis and conservative therapy of non-calcium kidney calculi. Ther Umsch Rev Ther. 2003; 60:89-97. DOI: https://doi.org/10.1024/0040-5930.60.2.89
  11. Ferrè S, Grange JS, Adams-Huet Ms B, et al. Effect of urine pH and magnesium on calcium oxalate saturation. Magnes Res. 2017;30:107-19. DOI: https://doi.org/10.1684/mrh.2018.0429
  12. Coe FL, Evan A, Worcester E. Pathophysiology-based treatment of idiopathic calcium kidney stones. Clin J Am Soc Nephrol 2011; 6:2083-92. DOI: https://doi.org/10.2215/CJN.11321210
  13. Siener R, Pitzer MS, Speller J, Hesse A. Risk Profile of patients with brushite stone disease and the impact of diet. Nutrients. 2023; 15:4092. DOI: https://doi.org/10.3390/nu15184092
  14. Parks JH, Coe FL, Evan AP, Worcester EM. Urine pH in renal calcium stone formers who do and do not increase stone phosphate content with time. Nephrol Dial Transplant 2009; 24:130-6. DOI: https://doi.org/10.1093/ndt/gfn420
  15. Guerra A, Ticinesi A, Allegri F, et al. Idiopathic calcium nephrolithiasis with pure calcium oxalate composition: clinical correlates of the calcium oxalate dihydrate/monohydrate (COD/COM) stone ratio. Urolithiasis. 2020; 48:271-9. DOI: https://doi.org/10.1007/s00240-019-01156-8
  16. Cheng WY, Tseng JS. Urinary stone analysis and clinical characteristics of 496 patients in Taiwan. Sci Rep. 2024; 14:14115. DOI: https://doi.org/10.1038/s41598-024-64869-w
  17. Ferrari P, Bonny O. Diagnosis and prevention of uric acid stones. Ther Umsch Rev Ther. 2004;61:571-4. DOI: https://doi.org/10.1024/0040-5930.61.9.571
  18. Pazos Pérez F. Uric acid renal lithiasis: new concepts. Contrib Nephrol. 2018; 192:116-24. DOI: https://doi.org/10.1159/000484286
  19. Wiederkehr MR, Moe OW. Uric acid nephrolithiasis: a systemic metabolic disorder. Clin Rev Bone Miner Metab. 2011; 9:207-17. DOI: https://doi.org/10.1007/s12018-011-9106-6
  20. Dello Strologo L, Laurenzi C, Emma F. Cystinuria. G Ital Nefrol 2010; 27:30-6.
  21. D’Ambrosio V, Capolongo G, Goldfarb D, et al. Cystinuria: an update on pathophysiology, genetics, and clinical management. Pediatr Nephrol Berl Ger. 2022; 37:1705-11. DOI: https://doi.org/10.1007/s00467-021-05342-y
  22. Amaro CRP, Goldberg J, Agostinho AD, et al. Metabolic investigation of patients with staghorn calculus: is it necessary? Int Braz J Urol Off J Braz Soc Urol. 2009; 35:658-61. DOI: https://doi.org/10.1590/S1677-55382009000600004
  23. Barbey F, Cachat F, Halabi G, et al. Infective lithiasis. Rev Med Suisse Romande 2004;124:465-9.
  24. Smith SN, Himpsl SD, Mobley HLT. Vaccination to protect against proteus mirabilis challenge utilizing the ascending model of urinary tract infection. Methods Mol Biol Clifton NJ. 2019;2021:201-15. DOI: https://doi.org/10.1007/978-1-4939-9601-8_18
  25. Osther PJ, Poulsen AL, Steven K. Stone risk after bladder substitution with the ileal-urethral Kock reservoir. Scand J Urol Nephrol. 2000; 34:257-61. DOI: https://doi.org/10.1080/003655900750041997
  26. Theisen KM, Ayyash O, Pere M, et al. Defining 24-hour urine parameters and kidney stone risk of student athletes. Clin Nephrol. 2022; 97:86-92. DOI: https://doi.org/10.5414/CN110355
  27. Yıldırım I, Koçan H. The pH of drinking water and its effect on the pH of urine. Cureus 2023;15:e47437. DOI: https://doi.org/10.7759/cureus.47437
  28. Piedras P, Cumpanas AD, McCormac A, et al. Alkaline water: help or hype for uric acid and cystine urolithiasis? J Urol. 2024;211:276-84. DOI: https://doi.org/10.1097/JU.0000000000003767
  29. Goodman JW, Asplin JR, Goldfarb DS. Effect of two sports drinks on urinary lithogenicity. Urol Res. 2009; 37:41-6. DOI: https://doi.org/10.1007/s00240-008-0166-0
  30. del Valle EE, Spivacow FR, Negri AL. Citrate and renal stones. Medicina (Mex) 2013; 73:363-8.
  31. Kamphuis GM, Wouter van Hattum J, de Bie P, Somani BK. Method of alkalization and monitoring of urinary pH for prevention of recurrent uric acid urolithiasis: a systematic review. Transl Androl Urol. 2019;8:S448-56. DOI: https://doi.org/10.21037/tau.2019.05.01
  32. Ong A, Brown G, Tokas T, et al. Selection and outcomes for dissolution therapy in uric acid stones: a systematic review of literature. Curr Urol Rep. 2023; 24:355-63. DOI: https://doi.org/10.1007/s11934-023-01164-7
  33. Marangella M. Use of citrate in patients with nephrolithiasis. G Ital Nefrol O2017; 34:51-60.
  34. Frolova EA, Tsarichenko DG, Saenko VS, et al. Dissolution of uric acid stones in the ureter. Urol Mosc Russ 1999. 2022; 6:56-60. DOI: https://doi.org/10.18565/urology.2022.6.56-60
  35. Shim M, Park HK. Multimodal treatments of cystine stones: an observational, retrospective single-center analysis of 14 cases. Korean J Urol. 2014; 55:515-9. DOI: https://doi.org/10.4111/kju.2014.55.8.515
  36. Hernandez Y, Costa-Bauza A, Calvó P, et al. Comparison of two dietary supplements for treatment of uric acid renal lithiasis: citrate vs. citrate + theobromine. Nutrients. 2020;12:2012. DOI: https://doi.org/10.3390/nu12072012
  37. Siener R, Struwe F, Hesse A. Effect of L-methionine on the risk of phosphate stone formation. Urology. 2016; 98:39-43. DOI: https://doi.org/10.1016/j.urology.2016.08.007
  38. Jarrar K, Boedeker RH, Weidner W. Struvite stones: long term follow up under metaphylaxis. Ann Urol. 1996; 30:112-7.
  39. Wall I, Tiselius HG. Long-term acidification of urine in patients treated for infected renal stones. Urol Int. 1990; 45:336-41. DOI: https://doi.org/10.1159/000281732
  40. European Association of Urology. EAU Guidelines on Urolithiasis. Edn. presented at the EAU Annual Congress Paris 2024. EAU Guidelines Office, Arnhem.
  41. Ettinger B, Pak CY, Citron JT, et al. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol. 1997; 158:2069-73. DOI: https://doi.org/10.1016/S0022-5347(01)68155-2
  42. Zerwekh JE, Odvina CV, Wuermser LA, Pak CYC. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest. J Urol. 2007; 177:2179-84. DOI: https://doi.org/10.1016/j.juro.2007.01.156
  43. Rodgers AL, Allie-Hamdulay S, Jackson GE, Sutton RAL. Enteric hyperoxaluria secondary to small bowel resection: use of computer simulation to characterize urinary risk factors for stone formation and assess potential treatment protocols. J Endourol. 2014; 28:985-94. DOI: https://doi.org/10.1089/end.2014.0077
  44. Zimmermann DJ, Voss S, von Unruh GE, Hesse A. Importance of magnesium in absorption and excretion of oxalate. Urol Int. 2005;74:262-7. DOI: https://doi.org/10.1159/000083560
  45. Krieger NS, Asplin JR, Frick KK, et al. Effect of potassium citrate on calcium phosphate stones in a model of hypercalciuria. J Am Soc Nephrol 2015; 26:3001-8. DOI: https://doi.org/10.1681/ASN.2014121223
  46. Siener R, Rüdy J, Herwig H, et al. Mixed stones: urinary stone composition, frequency and distribution by gender and age. Urolithiasis. 2024; 52:24. DOI: https://doi.org/10.1007/s00240-023-01521-8
  47. Grases F, Costa-Bauza A. Key Aspects of myo-inositol hexaphosphate (phytate) and pathological calcifications. Molecules. 2019; 24:4434. DOI: https://doi.org/10.3390/molecules24244434
  48. Curhan GC, Willett WC, Knight EL, Stampfer MJ. Dietary factors and the risk of incident kidney stones in younger women: nurses' health study II. Arch Intern Med. 2004; 164:885-891. DOI: https://doi.org/10.1001/archinte.164.8.885
  49. Saw NK, Chow K, Rao PN, Kavanagh JP. Effects of inositol hexaphosphate (phytate) on calcium binding, calcium oxalate crystallization and in vitro stone growth. J Urol. 2007; 177:2366-70. DOI: https://doi.org/10.1016/j.juro.2007.01.113
  50. Guimerà J, Martínez A, Bauza JL, et al. Effect of phytate on hypercalciuria secondary to bone resorption in patients with urinary stones: pilot study. Urolithiasis. 2022; 50:685-690. DOI: https://doi.org/10.1007/s00240-022-01357-8
  51. Conte A, Pizá P, García-Raja A, et al. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate). Arch Esp Urol. 1999;52:305-10.
  52. Hsu Y-C, Lin Y-H, Shiau L-D. Effects of various inhibitors on the nucleation of calcium oxalate in synthetic urine. Crystals 2020;10:333. DOI: https://doi.org/10.3390/cryst10040333
  53. Grases F, Rodriguez A, Costa-Bauza A. J Urol. 2015; 194:812-9. 54. DOI: https://doi.org/10.1016/j.juro.2015.03.099
  54. Najeeb Q, Masood I, Bhaskar N, et al. Effect of BMI and urinary pH on urolithiasis and its composition. Saudi J Kidney Dis Transplant 2013; 24:60-6. DOI: https://doi.org/10.4103/1319-2442.106243
  55. Park DJ, Kim BS, Kwon SO, et al. Clinical characteristics of surgically managed patients with asymptomatic renal stones: Comparison of patients with symptomatic renal stones. Investig Clin Urol. 2023;64:161-7. DOI: https://doi.org/10.4111/icu.20220271
  56. Prasanchaimontri P, Monga M. Predictive factors for kidney stone recurrence in type 2 diabetes mellitus. Urology. 2020;143:85-90. DOI: https://doi.org/10.1016/j.urology.2020.04.067
  57. Eisner BH, Porten SP, Bechis SK, Stoller ML. Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers. J Urol. 2010; 183:2244-8. DOI: https://doi.org/10.1016/j.juro.2010.02.007
  58. Tallman JE, Stone BV, Sui W, et al. Association between obstructive sleep apnea and 24-h urine chemistry risk factors for urinary stone disease. Urolithiasis. 2023; 51:46. DOI: https://doi.org/10.1007/s00240-023-01421-x
  59. De Coninck V, Keller EX, Rodríguez-Monsalve M, et al. Evaluation of a portable urinary pH meter and reagent strips. J Endourol. 2018; 32:647-52. DOI: https://doi.org/10.1089/end.2018.0202
  60. da Silva IBL, Amaro CP, Amaro JL, et al. Fasting and 24-h urine pH in patients with urolithiasis using potassium citrate. Am J Clin Exp Urol. 2022; 10:188-93.
  61. Murayama T, Sakai N, Yamada T, Takano T. Role of the diurnal variation of urinary pH and urinary calcium in urolithiasis: a study in outpatients. Int J Urol 2001; 8:525-31. DOI: https://doi.org/10.1046/j.1442-2042.2001.0366a.x
  62. NICE. Guideline NG118. Urolithiasis: assessment and management. National Institute for Health and Care Excellence; 2019.

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2025 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.